Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin

Br J Haematol. 2022 Jun;197(5):630-633. doi: 10.1111/bjh.18099. Epub 2022 Mar 4.

Authors

Vera Radici^{1

2}, Nicolas Stocker^{1

3}, Rémy Dulery^{1

3}, Eolia Brissot^{1

3}, Anne Bannet^{1

3}, Zoe van de Wyngaert^{1

3}, Simona Sestili^{1

3}, Ramdane Belhocine^{1

3}, Agnes Bonin¹, Tounes Ledraa^{1

3}, Mohamad Mohty^{1

3}, Florent Malard^{1

3}

Affiliations

¹ APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.
² Clinical Hematology and Bone Marrow Transplant Centre, S. Maria della Misericordia Hospital, University of Udine, Udine, Italy.
³ INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.

PMID: 35245388
DOI: 10.1111/bjh.18099

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antilymphocyte Serum / therapeutic use
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Graft vs Host Disease* / prevention & control
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Incidence
Transplantation Conditioning / adverse effects
Transplantation, Homologous / adverse effects

Substances

Antilymphocyte Serum